U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Migraine Headache

; .

Author Information and Affiliations

Last Update: August 23, 2023.

Continuing Education Activity

Migraine is a genetically influenced complex disorder characterized by episodes of moderate-to-severe headache, most often unilateral and generally associated with nausea and light and sound sensitivity. The word migraine is derived from the Greek word "hemikrania," which later was converted into Latin as "hemigranea." The French translation of such a term is "migraine." It is a common cause of disability and loss of work. Migraine attacks are complex brain events that unfold over hours to days in a recurrent matter. The most common type of migraine is without aura (75% of cases). This activity reviews the etiology and pathophysiology of migraine and highlights the role of the interprofessional team in evaluating and treating patients with this condition.


  • Identify the etiology of migraine headaches, medical conditions, and emergencies.
  • Review appropriate evaluation of a migraine headache.
  • Outline the management options available for migraine headaches.
  • Describe interprofessional team strategies for improving care coordination and communication to advance migraine headaches and improve outcomes.
Access free multiple choice questions on this topic.


Migraine is a genetically influenced complex disorder characterized by episodes of moderate-to-severe headache, most often unilateral and generally associated with nausea and increased sensitivity to light and sound. The word migraine is derived from the Greek word "hemikrania," later converted into Latin as "hemigranea." The French translation of such a term is "migraine."[1] Migraine is a common cause of disability and loss of work. Migraine attacks are complex brain events that unfold over hours to days in a recurrent matter. The most common type of migraine is without aura (75% of cases).

Migraines can be classified into subtypes according to the headache classification committee of the International Headache Society.[2] These subtypes are:

  • Migraine without aura is a recurrent headache attack of 4 to 72 hours; typically unilateral in location, pulsating in quality, moderate to severe in intensity, aggravated by physical activity, and associated with nausea and light and sound sensitivity (photophobia and phonophobia).
  • Migraine with aura has recurrent fully reversible attacks, lasting minutes, typically one or more of these unilateral symptoms: visual, sensory, speech and language, motor, brainstem, and retinal, usually followed by headache and migraine symptoms.
  • Chronic migraine is a headache that occurs on 15 or more days in a month for more than three months and has migraine features on at least eight or more days in a month.
  • Complications of migraine
    • Status migrainosus is a debilitating migraine attack that lasts more than 72 hours.
    • Persistent aura without infarction is an aura that persists for more than one week without evidence of infarction on neuroimaging.
    • Migrainous infarction is one or more aura symptoms associated with brain ischemia on neuroimaging during a typical migraine attack.
    • Migraine aura-triggered seizure occurs during an attack of migraine with aura, and a seizure is triggered. 
  • Probable migraine is a symptomatic migraine attack that lacks one of the features required to fulfill the criteria for one of the above and does not meet the criteria for another type of headache.
  • Episodic syndromes that may be associated with migraine
    • Recurrent gastrointestinal disturbances are recurrent attacks of abdominal pain and discomfort, nausea, and vomiting that may be associated with migraines.
    • Benign paroxysmal vertigo has brief recurrent attacks of vertigo.
    • Benign paroxysmal torticollis is recurrent episodes of head tilt to one side.


Genetics and Inheritance

Migraine has a strong genetic component. The risk of migraines in ill relatives is three times greater than that of relatives of non-ill subjects, but no inheritance pattern was identified.[3][4] The genetic basis of migraine is complex, and it is uncertain which loci and genes are the ones implicated in the pathogenesis; it may be based on more than one genetic source at different genomic locations acting in tandem with environmental factors to bring susceptibility and the characteristics of the disease in such individuals.[5] Identifying these genes in an individual with migraines could predict the targeted prophylactic treatment.

Familial Hemiplegic Migraine

  • Hemiplegic migraine can occur in families or sporadically (one individual, as the first member of the family to have a hemiplegic migraine).[6] Channelopathies cause the primary three types:
  • Type 1 is caused by mutations in the CACNA1A gene (calcium voltage-gated channel alpha 1A subunit) on chromosome 19p13.[7]
  • Type 2 is caused by mutations in the ATP1A2 gene (ATPase, Na+/K+ transporting alpha two subunit) on chromosome 1q23.[8]
  • Type 3 is caused by mutations in the SCN1A gene (sodium voltage-gated channel Type 1 alpha subunit).
  • Mutations in the PRRT2 (Proline-Rich transmembrane 2) gene are recognized as a possible cause.[9] PRRT2 gene encodes a protein that interacts with the SNAP25 (synaptosomal nerve-associated protein 25), which may pose a role in voltage-gated calcium channel regulation.[10]
  • Mutations in the SLC4A4 (solute carrier family four member 4) gene have also been associated with familial forms of migraine.[11]


It is a syndrome of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, a multisystemic disorder by maternal inheritance that can present recurrent migraine headaches.[12]


Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) angiopathy by autosomal dominant inheritance, caused by mutations in the NOTCH3 gene (notch receptor 3) on chromosome 19 that can present migraine with aura (prodrome in 80%) in nearly 50% of carriers.[13]


Retinal vasculopathy with cerebral leukodystrophy is angiopathy by C-terminal frame-shift mutations in TREX1 (three prime repair exonuclease 1) presents almost 60% of the cases.[14]


Hereditary infantile hemiparesis, retinal arteriolar tortuosity, and leukoencephalopathy


Hereditary endotheliopathy with retinopathy, nephropathy, and stroke


Withdrawn or exposure to several factors contribute to the development of migraine headaches.[15] A retrospective study found that 76% of the patients reported triggers.[16] Some are probable contributing factors, while others are only possible or unproven.

  • Stress in 80% (probable factor)
  • Hormonal changes in 65% during menstruation, ovulation, and pregnancy (probable factor)
  • Skipped meals 57% (probable factor)
  • Weather changes in 53% (probable factor)
  • Excessive or insufficient sleep in 50% (possible factor)
  • Odors in 40% (perfumes, colognes, petroleum distillates)
  • Neck pain in 38%
  • Exposure to lights in 38% (probable factor)
  • Alcohol ingestion in 38% (wine as a probable factor)
  • Smoking in 36% (unproven factor)
  • Late sleeping in 32%
  • Heat in 30%
  • Food in 27% (aspartame as a possible factor, and tyramine and chocolate as unproven factors)
  • Exercise in 22%
  • Sexual activity in 5%


Migraine is highly prevalent, affecting 12% of the population, attacking up to 17% of women and 6% of men yearly.[17][18][19] Among children, it tends to happen more in girls than boys.[20] The adjusted prevalence of migraine is highest in North America, followed by South America, Central America, Europe, Asia, and Africa. It is ranked as the second leading cause of disability worldwide.[21] Migraine tends to run in families.[17] There is a reported risk of 40% if one parent has a history of migraine, which increases to 75% when both parents have a migraine history.

It is consistently the fourth or fifth most common reason for emergency visits accounting for an annual 3% of all emergency visits.[22] Its prevalence increases in puberty but continues to increase until 35 to 39 years of age, decreasing later in life, especially after menopause.[18] Moreover, it is considered the second major cause of disability after back pain with respect to years of life lived with disability.[20]


Although not fully understood, pathogenesis involves multiple components of both the peripheral and central nervous systems. Some of the most understood concepts are described in this section.

According to the older vascular theory of migraine, headache is produced by vasodilation and aura by vasoconstriction, but this theory is no longer viable.[23] Nowadays, the suggestions pose that multiple primary neuronal impairments lead to a series of intracranial and extracranial changes that cause migraines.[24]

There is activation of trigeminal afferents by neuronal pannexin-1 mega channel opening and subsequent activation of caspase-1, followed by the release of proinflammatory mediators, activation of NF-kB (nuclear factor kappa-B), and spreading of this inflammatory signal to trigeminal nerve fibers around vessels of the pia mater.[25] This causes a series of cortical, meningeal, and brainstem events, provoking inflammation in the pain-sensitive meninges and resulting in headaches through central and peripheral mechanisms.[26][27] This pathway can, therefore, explain the cortical depression (which establishes the aura) and the latter prolonged activation of trigeminal nociception (which leads to headache).

The cortical spreading depression of Leão, a propagating wave of neuronal and glial depolarization that initiates a cascade, is hypothesized to cause the aura, activate trigeminal afferents, and alter the hematoencephalic barrier permeability by activating brain matrix metalloproteinases.[28] In migraine without aura, the suggestions are that cortical depression may occur in areas where depolarization is not consciously perceived, such as the cerebellum.[29]

The anterior structures are most innervated by the ophthalmic division of the trigeminal nerve, which could explain the pain in the anterior region of the head. There is a convergence of fibers from the upper cervical roots, which originate from trigeminal nerve neurons along with the trigeminal ganglion and the trigeminal nerve at the trigeminal nucleus caudalis, which can explain the anterior to the posterior distribution of pain, from where the fibers ascend to the thalamus and the sensory cortex.[30] 

Based on vasodilation, edema, and plasma protein extravasation, neurogenic inflammation results from nociceptor activation, in this case, the trigeminal system. It is associated with the release of substance P, calcitonin gene-related peptide, and neurokinin a, all vasoactive neuropeptides liberated by trigeminal ganglion stimulation.[31] Elevated levels of these neuropeptides have been found in the spinal fluid of chronic migraine patients.[32][33] Neurogenic inflammation can lead to sensitization, which is the process where neurons tend to become more responsive to stimulation. This can explain some clinical symptoms of the pain and the conversion from episodic migraine to chronic ones.[34]

Following neuropeptides are believed to play a role in pathogenesis:

  • Serotonin, released from the brainstem serotonergic nuclei, may play a role in migraine; however, the exact role of its mechanisms remains a matter of controversy. Most likely, serotonin levels are low between attacks because it may cause a deficiency in the serotonin pain inhibition system, therefore helping the activation of the trigeminal system. It could mediate by acting directly over the cranial vessels, in central pain control pathways, or by cortical projections of brainstem serotonergic nuclei.[35][36]
  • Calcitonin gene-related peptide (CGRP) is abundant in trigeminal ganglion neurons. It is released from the peripheral and central nerve terminals and secreted within the trigeminal ganglion. When released from the peripheral terminals, it initiates an increased synthesis of nitric oxide and later sensitization of trigeminal nerves.[37][38] It is a strong vasodilator of cerebral and dura mater vessels, therefore, a component of neurogenic inflammation, and it also mediates trigeminal pain transmission from vessels to the central nervous system.
  • Pituitary adenylate cyclase-activating polypeptide (PACAP) may also play an important role in mediating migraine attacks as its concentration is elevated during the attacks, and its infusion may trigger migraine in susceptible patients.

History and Physical

Four Phases of Migraine Attacks

Four phases have been identified in migraine attacks.[39]

Prodrome: premonitory symptoms associated with hypothalamus activation (dopamine)[40][41]

  • Around 77% of patients suffer prodromic symptoms for up to 24 to 48 hours before headache onset. It is more common in females than males (81 to 64%).
  • Frequent symptoms are yawning (34%), mood change, lethargy, neck symptoms, light sensitivity, restlessness, difficulties in focusing vision, feeling cold, craving, sound sensitivity, sweating, excess energy, thirst, and edema.

Aura: changes in cortical function, blood circulation, and neurovascular integration occur in about 25% of cases[2][13][42][43]

  • It can precede the headache, or it can present simultaneously.
  • They are typically gradual, less than 60 minutes in duration, more often visual, and have positive and negative symptoms.
    • Positive symptoms are caused by active release from central nervous system neurons (bright lines or shapes, tinnitus, noises, paresthesias, allodynia, or rhythmic movements).
    • Negative symptoms indicate a lack or loss of function (reduction or loss of vision, hearing, sensation, or motion).
  • They have to be fully reversible.
  • It usually consists of tingling sensations on one side of the face or a limb. They are considered paresthesias.
  • The most common positive visual symptom is the scintillating scotoma (an area of absent vision with a shimmering or glittering zigzag border).
  • The most common negative visual symptom is visual field defects.
  • Visual auras are the most frequent ones.
  • Sensory auras are also common. They can follow visual symptoms or occur without them.
  • Language auras are not frequent. They consist of transient dysphasia.
  • Motor auras are rare. They consist of complete or partial hemiplegia involving limbs and the face.

Headache: additional changes in blood circulation and function of the brainstem, thalamus, hypothalamus, and cortex

  • Often unilateral, generally with a pulsatile or throbbing feature and increasing intensity within the first hours.
  • The intensity can correlate to nausea, vomiting, photophobia, phonophobia, rhinorrhea, lachrymation, allodynia, and osmophobia.
  • It can take place over hours to days.
  • Patients may seek relief in dark places, as the pain usually resolves in sleep.

Postdrome: persistent blood changes with symptoms after headache termination

  • This phase consists of a movement-vulnerable pain in the same location as the previous headache.
  • Common symptoms can be exhaustion, dizziness, difficulty concentrating, and euphoria.


The diagnosis of migraine is based on patient history, physical examination, and fulfillment of the diagnostic criteria. The necessary information that has to be gathered consists of these simple questions:

  • Demographic features of the patient: age, gender, race, profession
  • When did the headache start?
  • Where does it hurt? Location, irradiation.
  • What is the intensity of the pain?
  • How is the pain? Which are the qualitative characteristics of pain?
  • How long does the pain last?
  • At which moment of the day does the pain appear?
  • How has it evolved since it started?
  • What is the frequency of appearance?
  • What are the triggering situations?
  • Simultaneous symptoms?
  • Is it related to sleep?
  • How does it get better or worse?
  • Which medications do you take to make it better? What is the frequency of this medication?

Patients should also be inquired about somatosensory disturbances, such as spreading unilateral numbness or tingling in the face and arm, as well as about disturbances in speech or thinking. Some aura symptoms, as described below, could indicate uncommon types of migraine:

  • Motor weakness
  • Dysarthria
  • Hypacusis
  • Diplopia
  • Ataxia
  • Vertigo
  • Tinnitus
  • Decreased level of consciousness

The International Classification of Headache Disorders (ICHD-3) describes these diagnostic criteria.[2]

B1. Migraine without aura:

B1a. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)

B1b. Headache has at least two of the following characteristics:

  • Unilateral location
  • Pulsating quality
  • Moderate or severe pain intensity
  • Aggravation by or causing avoidance of routine physical activity (walking or climbing stairs)

B1c. During a headache, at least one of the following:

  • Nausea and vomiting
  • Photophobia and phonophobia

B2. Migraine with aura:

B2a. One or more of the following fully reversible aura symptoms:

  • Visual
  • Sensory
  • Speech and language
  • Motor
  • Brainstem
  • Retinal

B2b. At least two of the following characteristics:

  • At least one aura symptom spreads gradually over five or more minutes
  • Two or more aura symptoms occur in succession
  • Each aura symptom lasts 5 to 60 minutes
  • At least one aura symptom is unilateral
  • At least one aura symptom is positive
  • The aura is accompanied, or followed within 60 minutes, by the headache.

C. On eight days or more per month for more than three months, fulfilling any of the following:

  • Criteria B1b and B1c for migraine without aura
  • Criteria B2a and B2b for migraine with aura
  • It is believed by the patient to be migraine headaches at onset and relieved by a triptan or ergot derivative.

D. Not better accounted for by another ICHD-3 diagnosis

The ICHD-3 Criteria for Migraine Without Aura

  1. At least five attacks fulfilling criteria B to D (see below)
  2. Headache attacks that last 4 to 72 hours, untreated or unsuccessfully treated
  3. Headache that has at least two of the following criteria:
    • Unilateral location
    • Pulsating quality
    • Moderate to severe pain intensity.
    • Aggravation by or causing avoidance of routine physical activity (such as walking or climbing stairs)
  4. During headaches, at least one of the following:
    • Nausea, vomiting, or both
    • Photophobia and phonophobia
  5. Not better accounted for by another ICHD-3 diagnosis

 The ICHD-3 Criteria for Migraine With Aura

  1. At least two attacks fulfilling criteria B to D
  2. One or more of the following fully reversible aura symptoms:
    • Visual
    • Sensory
    • Speech and language
    • Motor
    • Brainstem
    • Retinal
  3. At least three of the following six characters:
    • At least one aura symptom spreads gradually over ≥5 minutes
    • Two or more symptoms occur in succession
    • Each aura symptom lasts 5 to 60 minutes
    • At least one aura symptom is unilateral
    • At least one aura symptom is positive
    • The aura is accompanied, or followed within 60 minutes, by the headache
  4. It is not better accounted for by another ICHD-3 diagnosis
  5. Hemiplegic migraine is diagnosed when the aura consists of motor weakness.
  6. Migraine with brainstem aura (previously known as basilar artery migraine or basilar migraine) is diagnosed if the aura symptoms emerge from the brainstem (bilateral hemianopic visual disturbance, diplopia, vertigo, ataxia, dysarthria, tinnitus, hyperacusis, bilateral paresthesia, or numbness)
  7. Retinal migraine is diagnosed when the aura involves a monocular visual field defect.

The ICHD-3 Criteria for Chronic Migraine

  1. Headache (tension-type-like or migraine-like) on 15 or more days per month for more than three months and fulfilling criteria B and C
  2. It occurs in a patient who has had at least five attacks fulfilling the following criteria for migraine without aura (B1) or migraine with aura (B2)

Neuroimaging (computed tomographic scan, magnetic resonance imaging, magnetic resonance angiography, or magnetic resonance venography) is indicated in the following cases:[44][45]

  • Acute severe headache, especially if it is the first or worst episode (discard subarachnoid hemorrhage)
  • Abnormal neurologic examination, especially if there are unexplained symptoms or signs (confusion, stiff neck, papilledema, epilepsy)
  • Non-typical characteristics
  • Changes in the patient's typical features or patterns
  • New episodes in older (> 50 years of age) or immunosuppressed patients
  • Systemic or meningeal signs or symptoms (fever, weight loss, fatigue)
  • New neurological symptoms or signs on examination
  • Headache not responding to treatment
  • Headache lasting > 72 hours
  • A significant change in the frequency, pattern, or severity of headaches
  • Severe headache pain ("worst headache of life") or headache causing awakening from sleep
  • New-onset headache in patients with HIV infection or cancer
  • Associated symptoms or signs suggestive of meningitis or stroke

The commonly used acronym "SNOOP" can be used to aid in the determination of neuroimaging indications:

  • "S" for systemic signs or symptoms and secondary risk factors
  • "N" for neurologic signs or symptoms
  • "O" for onset
  • "O" for older
  • "P" for position-dependent intensity changes, the prior pattern changes, papilledema, and precipitated by Valsalva maneuvers.

Cerebrospinal fluid analysis and electroencephalogram are not typically performed unless seizure activity of infectious etiology has to be excluded.

Treatment / Management

Treatment options are based on the onset scenarios: acute or chronic.

Acute or Abortive Treatment

Acute treatment aims to stop the progression of a headache. It has to be treated quickly and with a large single dose. Oral agents can be ineffective in patients with migraine-induced gastric stasis. Therefore, parenteral medication could be the rule for some patients, especially the ones with nausea or vomiting.[46][47][48] Therapy consists of stratified options:

  • NSAIDs (nonsteroidal anti-inflammatory drugs): Ibuprofen (400 to 600 mg), naproxen (275 to 825 mg), diclofenac (65 mg), aspirin (900 to 1000 mg), or acetaminophen (1000 mg).[49] Usually, in mild to moderate attacks without nausea or vomiting. If one NSAID is ineffective, another class of drug should be used.
  • Triptans (the first line in patients with allodynia): Sumatriptan (administered as a subcutaneous injection of 6 mg, a nasal spray of 20 to 40 mg over 24 hours, a nasal powder of 10 to 30 mg over 24 hours, or orally 50 to 100 mg once), zolmitriptan 10 mg per 24 hours (nasal 2.5 to 5 mg as a single dose and oral 2.5 mg as a single dose), eletriptan, rizatriptan, almotriptan. They might be used with or without naproxen for moderate to severe attacks. Unlike NSAIDs, patients who do not respond well to one triptan may respond to another; therefore, therapy may be individualized.
    • To avoid medication overuse, triptans should be limited to less than ten days of use within a month.
    • Because of the activation of the 5-HT(1B) and 5-HT(1D) receptors on coronary arteries and cerebral vessels, there are recommendations against its use in patients with ischemic stroke, ischemic heart disease, poor-controlled hypertension, angina, pregnancy, hemiplegic or basilar migraine. In these patients with cardiovascular risks, the best-suited medication is a selective serotonin 1F receptor agonist that does not produce vasoconstriction; lasmiditan.
    • It is recommended to monitor therapy if the patient takes selective serotonin reuptake inhibitors or selective serotonin-noradrenaline reuptake inhibitors because of the risk of serotonin syndrome.
    • The combination of nonsteroidal anti-inflammatory drugs (NSAID) with triptan appears more effective than using either drug class alone. In a single tablet, sumatriptan succinate 85 mg and naproxen sodium 500 mg may be prescribed as initial therapy.[50]
  • Antiemetics: Metoclopramide, chlorpromazine, or prochlorperazine. They are generally used as adjunctive therapy with NSAIDs or triptans to decrease nausea and vomiting, especially in the emergency department. Diphenhydramine can also be added to prevent dystonic reactions (mostly metoclopramide).
  • Calcitonin-gene-related peptide antagonists: Rimegepant (75 mg as a single dose) or ubrogepant could be considered in patients who don't respond to conventional treatment or those with coronary artery disease.[51]
  • Selective serotonin 1F receptor agonist: US Food and Drug Administration (FDA) approved lasmiditan oral tablets in October 2019 for the acute treatment of migraine in adults. The initial dose of lasmiditan is 50 or 100 mg, particularly effective for patients who cannot use triptans due to cardiovascular risks. The dose may be increased to 100 or 200 mg per requirement, but no more than one dose should be taken over 24 hours. However, one significant side effect is dizziness. So patients should not engage in potentially hazardous activities or drive a motor vehicle for at least eight hours after each dose of lasmiditan.[52]
  • Ergots: Ergotamine and dihydroergotamine (intravenous (IV), intramuscular (IM), subcutaneous, and intranasal use) are recommended for acute attacks as a parenteral administration and effective as bridge therapy for medication overuse headache and status migrainosus. Ergotamine has not demonstrated particular effectiveness yet and can present significant side effects, including cerebrovascular, cardiovascular, and peripheral ischemic complications.
  • Dexamethasone can reduce the recurrence of early headaches but does not provide immediate relief.[53][54]
  • Transcutaneous supraorbital nerve stimulation can reduce intensity.[55]
  • Transcranial magnetic stimulation is proved effective as a second-line treatment, with no serious side effects. It can also be offered as an option to treat chronic migraines. It is contraindicated in patients with epilepsy.[56][57][58]
  • Nonpainful remote electric neurostimulation could be considered a first-line treatment in some patients.[59][60]
  • Peripheral nerve blocking (occipital plexus and sphenopalatine ganglion) may also be tried.[61][62]

Prophylactic or Preventive Treatment

Preventive treatment aims to reduce attack frequency, improve responsiveness to acute attacks' severity and duration, and reduce disability.[63][64] Migraine triggers have to be documented by each individual to reduce them in the future.

  • Indications for preventive treatment are:
    • Frequent or long-lasting headaches
    • Attacks that cause significant disability and reduced quality of life
    • Contraindications or failure to acute therapies
    • Significant adverse effects of abortive therapies
    • Risk of medication overuse headache
    • Menstrual migraine (along with short-term premenstrual prophylaxis)
    • Hemiplegic migraine
    • Brainstem aura migraine
    • Persistent aura without infarction
    • Migrainous infarction
  • Preventive treatment agents are the following:
    • Beta-blockers: Metoprolol and propranolol - especially in hypertensive and non-smoker patients
    • Antidepressants: Amitriptyline and venlafaxine - especially in patients with depression or anxiety disorders and insomnia
    • Anticonvulsants: Valproate acid and topiramate - especially in epileptic patients
    • Calcium channel blockers: Verapamil and flunarizine - especially in women of childbearing age or patients with Raynaud's phenomenon
    • Calcitonin gene-related peptide antagonists: Erenumab, fremanezumab, and galcanezumab

Alternative Treatment 

  • Lifestyle changes; must be a commitment from the patient; however, social support is of great importance to improve mental health to help the patient's involvement.
  • Regular exercise
  • Yoga
  • Relaxation training
  • Cognitive-behavioral therapy
  • Biofeedback
  • Reduction of triggers
  • Detoxification
  • Butterbur
  • Melatonin

Differential Diagnosis

The following should be considered in a patient with a migraine:

  • Tension-type headache
  • Cluster headache
  • Cerebral aneurysms
  • Chronic paroxysmal hemicrania
  • Dissection syndromes
  • Encephalitis
  • Subarachnoid/intracranial hemorrhage
  • Meningitis
  • Temporal/giant cell arteritis

Tension-type headache is usually bilateral, lasting 30 minutes to 7 days. The patient feels pressure or tightness but remains active. There are no associated symptoms.

Cluster headache is unilateral and has a sudden start around the eye or temple. It progresses in intensity within minutes to an excruciating continuous deep pain. It lasts 15 minutes to 3 hours. Associated symptoms include lacrimation and redness of the eye, rhinorrhea, pallor, sweating, Horner syndrome, agitation, and focal neurologic symptoms. It can easily be provoked by alcohol.

Treatment Planning

 Table 1. Acute Therapy*Adverse effects in this section pertain to all triptans unless specified

Table Icon


Aspirin[49] Ibuprofen

Table Icon


Table 2. Preventive therapy for migraine[78].


A migraine is a chronic condition that can revert to episodic migraine in 26 to 70% of patients. Prolonged remissions are common; however, some patients have a pattern of leaving and returning to chronic states. The severity and frequency of attacks can diminish with age.[81] Episodes increase during puberty but continue to climb until 35 to 39 years of age, decreasing later in life, especially after menopause.[18]


  • Status migrainosus, a debilitating migraine attack lasting over 72 hours
  • Migrainous infarction
  • Migraine aura-triggered seizure
  • Persistent aura without infarction
  • Work disability
  • Loss of work


Patients may be managed by a wide variety of healthcare professionals, including internists, family physicians, pain specialists, and neurologists.

Deterrence and Patient Education

Timely diagnosis and management of migraine headaches are essential, as they can sometimes be debilitating and affect the quality of life. Patients should be educated about the different phases of migraine headaches and the benefits of abortive and prevention therapy. Patients should be educated about lifestyle changes, which can help in reducing the frequency and severity of migraine attacks. Patients should also be instructed to go to a doctor in case of worsening symptoms or the occurrence of new neurological symptoms, which might warrant neuroimaging.

Pearls and Other Issues

  • Cortical spreading depression is the probable cause of the aura. It can activate trigeminal nerve afferents and alter hematoencephalic barrier permeability. Trigeminovascular system activation can initiate neurogenic inflammation related to migraine headaches.
  • The attacks are recurrent and occur through a cascade of events over hours to days.
  • Typical migraines progress through a prodrome, an aura, a headache, and the postdrome.
  • There is no one approach to treating migraines. Each case must be individualized according to its comorbidities.

Enhancing Healthcare Team Outcomes

Management of a migraine patient will require the efforts of an interprofessional healthcare team. The interprofessional care provided to the patient must use an integrated care pathway combined with an evidence-based approach to planning and evaluating all joint activities. Primary care clinicians (MDs, DOs, NPs, and PAs) obtain the assistance of an internist, a neurologist, or a headache specialist if there's any doubt about the diagnosis. Nurses and psychologists can assist team management by teaching lifestyle changes, mental health supervision, drug overuse detoxification, and medication use recommendations.

Pharmacists can aid the team in checking for appropriate dosing and determining drug interactions, especially if the patient is treated for chronic migraines. Nursing must coordinate activities between the various disciplines and often serve as initial contact points for patients and other team members. All interprofessional team members must document any changes in patient status as they observe them and notify the appropriate other parties on the healthcare team so additional diagnostic and/or therapeutic measures can occur if necessary. Open communication among team members is crucial to optimal patient care.

An interprofessional team that provides an integrated approach to patient care can help achieve the best possible outcomes. Collaboration, shared decision-making, and communication are crucial for a good result. [Level 5]

Review Questions


Rose FC. The history of migraine from Mesopotamian to Medieval times. Cephalalgia. 1995 Oct;15 Suppl 15:1-3. [PubMed: 8749238]
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. [PubMed: 29368949]
Merikangas KR, Risch NJ, Merikangas JR, Weissman MM, Kidd KK. Migraine and depression: association and familial transmission. J Psychiatr Res. 1988;22(2):119-29. [PubMed: 3404480]
Devoto M, Lozito A, Staffa G, D'Alessandro R, Sacquegna T, Romeo G. Segregation analysis of migraine in 128 families. Cephalalgia. 1986 Jun;6(2):101-5. [PubMed: 3527442]
de Vries B, Anttila V, Freilinger T, Wessman M, Kaunisto MA, Kallela M, Artto V, Vijfhuizen LS, Göbel H, Dichgans M, Kubisch C, Ferrari MD, Palotie A, Terwindt GM, van den Maagdenberg AM., International Headache Genetics Consortium. Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set. Cephalalgia. 2016 Jun;36(7):604-14. [PubMed: 25633374]
Riant F, Ducros A, Ploton C, Barbance C, Depienne C, Tournier-Lasserve E. De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine. Neurology. 2010 Sep 14;75(11):967-72. [PubMed: 20837964]
Jen JC, Kim GW, Dudding KA, Baloh RW. No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Arch Neurol. 2004 Jun;61(6):926-8. [PubMed: 15210532]
Costa C, Prontera P, Sarchielli P, Tonelli A, Bassi MT, Cupini LM, Caproni S, Siliquini S, Donti E, Calabresi P. A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. Cephalalgia. 2014 Jan;34(1):68-72. [PubMed: 23918834]
Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain. 2015 Dec;138(Pt 12):3476-95. [PubMed: 26598493]
Jarvis SE, Zamponi GW. Masters or slaves? Vesicle release machinery and the regulation of presynaptic calcium channels. Cell Calcium. 2005 May;37(5):483-8. [PubMed: 15820397]
Suzuki M, Van Paesschen W, Stalmans I, Horita S, Yamada H, Bergmans BA, Legius E, Riant F, De Jonghe P, Li Y, Sekine T, Igarashi T, Fujimoto I, Mikoshiba K, Shimadzu M, Shiohara M, Braverman N, Al-Gazali L, Fujita T, Seki G. Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. Proc Natl Acad Sci U S A. 2010 Sep 07;107(36):15963-8. [PMC free article: PMC2936614] [PubMed: 20798035]
Lee HN, Eom S, Kim SH, Kang HC, Lee JS, Kim HD, Lee YM. Epilepsy Characteristics and Clinical Outcome in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). Pediatr Neurol. 2016 Nov;64:59-65. [PubMed: 27671241]
Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Goadsby PJ, Charles A. Migraine headache is present in the aura phase: a prospective study. Neurology. 2012 Nov 13;79(20):2044-9. [PMC free article: PMC3511920] [PubMed: 23115208]
Stam AH, Kothari PH, Shaikh A, Gschwendter A, Jen JC, Hodgkinson S, Hardy TA, Hayes M, Kempster PA, Kotschet KE, Bajema IM, van Duinen SG, Maat-Schieman MLC, de Jong PTVM, de Smet MD, de Wolff-Rouendaal D, Dijkman G, Pelzer N, Kolar GR, Schmidt RE, Lacey J, Joseph D, Fintak DR, Grand MG, Brunt EM, Liapis H, Hajj-Ali RA, Kruit MC, van Buchem MA, Dichgans M, Frants RR, van den Maagdenberg AMJM, Haan J, Baloh RW, Atkinson JP, Terwindt GM, Ferrari MD. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain. 2016 Nov 01;139(11):2909-2922. [PMC free article: PMC5091044] [PubMed: 27604306]
Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med Clin North Am. 2001 Jul;85(4):911-41. [PubMed: 11480265]
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007 May;27(5):394-402. [PubMed: 17403039]
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001 Jul-Aug;41(7):646-57. [PubMed: 11554952]
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF., AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9. [PubMed: 17261680]
Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017 Jan;16(1):76-87. [PubMed: 27836433]
MacGregor EA. Migraine. Ann Intern Med. 2017 Apr 04;166(7):ITC49-ITC64. [PubMed: 28384749]
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):954-976. [PMC free article: PMC6191530] [PubMed: 30353868]
Burch R, Rizzoli P, Loder E. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache. 2018 Apr;58(4):496-505. [PubMed: 29527677]
Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, Larsson HB, Olesen J, Ashina M. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 2013 May;12(5):454-61. [PubMed: 23578775]
Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015 Apr 29;35(17):6619-29. [PMC free article: PMC4412887] [PubMed: 25926442]
Karatas H, Erdener SE, Gursoy-Ozdemir Y, Lule S, Eren-Koçak E, Sen ZD, Dalkara T. Spreading depression triggers headache by activating neuronal Panx1 channels. Science. 2013 Mar 01;339(6123):1092-5. [PubMed: 23449592]
Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019 Dec 23;20(1):117. [PMC free article: PMC6929435] [PubMed: 31870279]
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002 Feb;8(2):136-42. [PubMed: 11821897]
Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, Wang X, Rosenberg GA, Lo EH, Moskowitz MA. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004 May;113(10):1447-55. [PMC free article: PMC406541] [PubMed: 15146242]
Takano T, Nedergaard M. Deciphering migraine. J Clin Invest. 2009 Jan;119(1):16-9. [PMC free article: PMC2613455] [PubMed: 19104145]
Pritlove-Carson S, Palmer RM, Morgan PR, Floyd PD. Immunohistochemical analysis of cells attached to teflon membranes following guided tissue regeneration. J Periodontol. 1992 Dec;63(12):969-73. [PubMed: 1282152]
Matsuda M, Huh Y, Ji RR. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J Anesth. 2019 Feb;33(1):131-139. [PMC free article: PMC6813778] [PubMed: 30448975]
Riesco N, Cernuda-Morollón E, Pascual J. Neuropeptides as a Marker for Chronic Headache. Curr Pain Headache Rep. 2017 Apr;21(4):18. [PubMed: 28281109]
Anapindi KDB, Yang N, Romanova EV, Rubakhin SS, Tipton A, Dripps I, Sheets Z, Sweedler JV, Pradhan AA. PACAP and Other Neuropeptide Targets Link Chronic Migraine and Opioid-induced Hyperalgesia in Mouse Models. Mol Cell Proteomics. 2019 Dec;18(12):2447-2458. [PMC free article: PMC6885698] [PubMed: 31649062]
Su M, Yu S. Chronic migraine: A process of dysmodulation and sensitization. Mol Pain. 2018 Jan-Dec;14:1744806918767697. [PMC free article: PMC5900816] [PubMed: 29642749]
Deen M, Christensen CE, Hougaard A, Hansen HD, Knudsen GM, Ashina M. Serotonergic mechanisms in the migraine brain - a systematic review. Cephalalgia. 2017 Mar;37(3):251-264. [PubMed: 27013238]
Deen M, Hansen HD, Hougaard A, Nørgaard M, Eiberg H, Lehel S, Ashina M, Knudsen GM. High brain serotonin levels in migraine between attacks: A 5-HT4 receptor binding PET study. Neuroimage Clin. 2018;18:97-102. [PMC free article: PMC5790018] [PubMed: 29387527]
Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019 May;59(5):659-681. [PMC free article: PMC6593989] [PubMed: 30982963]
Edvinsson L. Role of CGRP in Migraine. Handb Exp Pharmacol. 2019;255:121-130. [PubMed: 30725283]
Charles A. The evolution of a migraine attack - a review of recent evidence. Headache. 2013 Feb;53(2):413-9. [PubMed: 23278169]
Karsan N, Goadsby PJ. Imaging the Premonitory Phase of Migraine. Front Neurol. 2020;11:140. [PMC free article: PMC7109292] [PubMed: 32269547]
Laurell K, Artto V, Bendtsen L, Hagen K, Häggström J, Linde M, Söderström L, Tronvik E, Wessman M, Zwart JA, Kallela M. Premonitory symptoms in migraine: A cross-sectional study in 2714 persons. Cephalalgia. 2016 Sep;36(10):951-9. [PubMed: 26643378]
Hansen JM, Charles A. Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs. J Headache Pain. 2019 Sep 06;20(1):96. [PMC free article: PMC6734209] [PubMed: 31492106]
van Dongen RM, Haan J. Symptoms related to the visual system in migraine. F1000Res. 2019;8 [PMC free article: PMC6668047] [PubMed: 31448081]
Evans RW. Diagnostic Testing for Migraine and Other Primary Headaches. Neurol Clin. 2019 Nov;37(4):707-725. [PubMed: 31563228]
Hawasli AH, Chicoine MR, Dacey RG. Choosing Wisely: a neurosurgical perspective on neuroimaging for headaches. Neurosurgery. 2015 Jan;76(1):1-5; quiz 6. [PMC free article: PMC4861636] [PubMed: 25255253]
Hsu YC, Lin KC, Taiwan Headache Society TGSOTHS. Medical Treatment Guidelines for Acute Migraine Attacks. Acta Neurol Taiwan. 2017 Jun 15;26(2):78-96. [PubMed: 29250761]
Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015 Jul-Aug;55 Suppl 4:221-35. [PubMed: 26178694]
Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun;55(6):778-93. [PubMed: 25877672]
Biglione B, Gitin A, Gorelick PB, Hennekens C. Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers. Am J Med. 2020 Apr;133(4):412-416. [PubMed: 31712099]
Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 04;297(13):1443-54. [PubMed: 17405970]
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019 Dec 05;381(23):2230-2241. [PubMed: 31800988]
Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB., COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018 Dec 11;91(24):e2222-e2232. [PMC free article: PMC6329326] [PubMed: 30446595]
Giamberardino MA, Affaitati G, Costantini R, Guglielmetti M, Martelletti P. Acute headache management in emergency department. A narrative review. Intern Emerg Med. 2020 Jan;15(1):109-117. [PubMed: 31893348]
Mirbaha S, Delavar-Kasmaei H, Erfan E. Effectiveness of the Concurrent Intravenous Injection of Dexamethasone and Metoclopramide for Pain Management in Patients with Primary Headaches Presenting to Emergency Department. Adv J Emerg Med. 2017 Fall;1(1):e6. [PMC free article: PMC6548094] [PubMed: 31172058]
Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia. 2019 Jan;39(1):3-14. [PMC free article: PMC6348457] [PubMed: 30449151]
Lan L, Zhang X, Li X, Rong X, Peng Y. The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails. J Headache Pain. 2017 Aug 22;18(1):86. [PMC free article: PMC5567575] [PubMed: 28831756]
Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, Goadsby PJ. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015;16:535. [PMC free article: PMC4463955] [PubMed: 26055242]
Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018 May;38(6):1038-1048. [PMC free article: PMC5944078] [PubMed: 29504483]
Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019 Sep;59(8):1240-1252. [PMC free article: PMC6767146] [PubMed: 31074005]
Rapoport AM, Bonner JH, Lin T, Harris D, Gruper Y, Ironi A, Cowan RP. Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. J Headache Pain. 2019 Jul 22;20(1):83. [PMC free article: PMC6734294] [PubMed: 31331265]
Korucu O, Dagar S, Çorbacioglu ŞK, Emektar E, Cevik Y. The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. Acta Neurol Scand. 2018 Sep;138(3):212-218. [PubMed: 29744871]
Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E. Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia. Headache. 2019 Sep;59(8):1229-1239. [PMC free article: PMC6771650] [PubMed: 31342515]
Tfelt-Hansen PC. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2013 Feb 26;80(9):869-70. [PubMed: 23439705]
Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, Aube M, Leroux E, Becker WJ., Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80. [PubMed: 23968886]
Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020 Jan;60(1):58-70. [PMC free article: PMC7003821] [PubMed: 31647577]
Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA. Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database Syst Rev. 2016 Dec 27;12(12):CD012227. [PMC free article: PMC6463878] [PubMed: 28027389]
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev. 2014 May 28;2014(5):CD009108. [PMC free article: PMC6469574] [PubMed: 24865446]
Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD009663. [PMC free article: PMC4164476] [PubMed: 22336867]
Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, Hassani H. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther. 2000 Aug;22(8):970-80. [PubMed: 10972633]
Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997 Nov;49(5):1210-8. [PubMed: 9371896]
Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008 Apr;28(4):383-91. [PubMed: 18294251]
Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev. 2001;(3):CD003224. [PubMed: 11687056]
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012 Feb;52(2):292-306. [PubMed: 22309235]
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737-745. [PubMed: 31311674]
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019 Nov 19;322(19):1887-1898. [PMC free article: PMC6865323] [PubMed: 31742631]
Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019 Jul 01;142(7):1894-1904. [PMC free article: PMC6620826] [PubMed: 31132795]
Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021 Sep;61(8):1214-1226. [PMC free article: PMC9292844] [PubMed: 34363701]
Modi S, Lowder DM. Medications for migraine prophylaxis. Am Fam Physician. 2006 Jan 01;73(1):72-8. [PubMed: 16417067]
Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ. 2010 Apr 20;182(7):E269-76. [PMC free article: PMC2855933] [PubMed: 20159899]
Markley HG. Verapamil and migraine prophylaxis: mechanisms and efficacy. Am J Med. 1991 May 17;90(5A):48S-53S. [PubMed: 2039020]
Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, Buse DC. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017 Oct 04;18(1):101. [PMC free article: PMC5628086] [PubMed: 28980171]

Disclosure: Marco Pescador Ruschel declares no relevant financial relationships with ineligible companies.

Disclosure: Orlando De Jesus declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK560787PMID: 32809622


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...